Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor
The proposed share-based settlement would extinguish approximately $100,000 of debt, subject to final exchange approval.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rhelion Life Sciences (TRUFF) has signed a new agreement reappointing Dr. Robin Carhart-Harris as scientific advisor to the company and Filament Health. He will meet regularly with management, advise on research programs and introduce researchers, clinicians and academic institutions, serving in a personal capacity.
Rhelion also agreed to settle approximately $100,000 owed to an arm's length creditor for a prior Filament obligation by issuing 3,333,333 common shares at $0.03 each. Completion is planned for the first date permitted under Canadian Securities Exchange policies and remains subject to final exchange approval.
The company granted 2,300,000 stock options to employees and consultants, exercisable at $0.05 per common share for five years from grant. Rhelion completed its acquisition of Filament on April 30, 2026, including PEX010 and 78 issued patents across 13 patent families.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFilament acquisition completed April 30, 2026, adding PEX010 and 78 issued patents across 13 patent families.
- Minor point. Forward-looking: it has not happened yet and may not happen.Proposed settlement would eliminate approximately $100,000 owed for a prior Filament obligation.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Proposed issuance of 3,333,333 common shares at $0.03 each would dilute existing shareholders.
- Minor pointDebt settlement remains subject to final Canadian Securities Exchange approval.
- Minor point. Forward-looking: it has not happened yet and may not happen.2,300,000 stock options granted at $0.05 per share create potential dilution over their five-year term.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Dr. Robin Carhart-Harris has signed a new agreement to serve as Scientific Advisor to Rhelion Life Sciences and its wholly owned subsidiary Filament Health.
Toronto, Ontario--(Newsfile Corp. - October 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research and compassionate access programs at leading institutions worldwide.
The Company is pleased to announce that Dr. Robin Carhart-Harris has signed a new agreement to serve as Scientific Advisor to the Company. Dr. Carhart-Harris first joined the Company as Scientific Advisor in June 2025.
Dr. Carhart-Harris will meet regularly with the Company's management, give scientific and strategic input on the Company's research programs, and make introductions to researchers, clinicians and academic institutions. Dr. Carhart-Harris is the Ralph Metzner Distinguished Professor of Neurology and Psychiatry at the University of California, San Francisco, and previously founded the Centre for Psychedelic Research at Imperial College London. He advises the Company in a personal capacity.
"Psychedelic science is at an exciting point," said Dr. Carhart-Harris. "I look forward to helping the team progress their own research and support researchers around the world."
"Robin has been a trusted voice for us since he first joined, and we are very happy to have him with us again," said Todd Shapiro, CEO and Director of Rhelion. "With Filament now part of Rhelion, his guidance and network will help us support more researchers with standardized natural psilocybin and potentially help us with our own clinical trial development."
PEX010, Filament Health's botanical psilocybin drug candidate, underscores Filament's position as a leading supplier of pharmaceutical grade natural psilocybin, supporting more than 80 academic and philanthropic research studies worldwide. PEX010 is available in a standardized dosing range of 1, 5 and 25 mg from a single drug candidate, with a 0.5 mg dose to follow, produced using Filament's proprietary and patented extraction, purification and stabilization methods, giving investigators consistent composition across every dose, every study and every research site. On April 30, 2026, the Company completed its previously announced acquisition of Filament Health Corp., including its lead drug candidate, PEX010, and its portfolio of 78 issued patents across 13 patent families.
Proposed Debt Settlement
The Company also announces that it has agreed to settle indebtedness of approximately
The Company intends to complete the Debt Settlement on the first date permitted under the policies of the Canadian Securities Exchange (the "CSE") following the dissemination of this news release.
The Debt Settlement remains subject to the final approval of the CSE. All securities issued in connection with the Debt Settlement will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities laws and CSE policies.
Grant of Options
The Company further announces that it has granted an aggregate of 2,300,000 stock options (the "Options") to certain employees and consultants of the Company and its subsidiaries pursuant to the Company's equity incentive plan. Each Option is exercisable at a price of
About Rhelion Life Sciences:
Rhelion Life Sciences is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the Company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with leading institutions around the world.
For additional information:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: todd@rhelion.com
Website: www.Rhelion.com
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current conditions but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Examples of such information include statements with respect to: the advisory relationship with Dr. Carhart-Harris and its expected benefits to the Company; the potential development by the Company of its own clinical trials; the Company's research programs and its academic, clinical, regulatory and commercial relationships; the continued supply of PEX010 to research studies; demand for standardized natural psilocybin; the anticipated future availability of a 0.5 mg dose alongside the existing 1, 5 and 25 mg doses; the expected integration of Filament's clinical infrastructure and intellectual property; the future development, commercialization and regulatory approval of PEX010; the Company's intention to complete the Debt Settlement, including the issuance of the Settlement Shares to the Creditor and the terms thereof; the timing of completion of the Debt Settlement; and the receipt of final CSE approval for the Debt Settlement.
Forward-looking information in this news release is based on certain assumptions and expected future events, namely: the continuation of the advisory relationship with Dr. Carhart-Harris; the Company's ability to benefit from his scientific input and introductions; the Company's ability to fund and advance its own clinical trial development; the continued ability of Filament and Psilo Scientific Ltd. to manufacture and supply PEX010; the completion of development of the 0.5 mg dose of PEX010 on the anticipated basis; the ability to obtain and maintain any required regulatory permits and approvals, including clinical trial, ethics, import and export authorizations; the successful integration of Filament Health following the completed acquisition; the receipt of final CSE approval of the Debt Settlement on the terms set out herein; the performance by the Company and the Creditor of their respective obligations in connection with the Debt Settlement, including the issuance and delivery of the Settlement Shares by the Company within the time contemplated; and general business, market and economic conditions. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, namely: the risk that the advisory relationship ends or changes; the risk that the Company does not realize the expected benefits of the advisory relationship, including new research or commercial relationships; the risk that the Company does not pursue, or is unable to fund or advance, its own clinical trial development; delays in regulatory permitting, including clinical trial, ethics, import and export authorizations; regulatory or enforcement developments affecting the legal framework for psilocybin supply and research; the risk that the 0.5 mg dose does not become available as anticipated; the risk that integration of Filament Health is not completed as anticipated; the risk that the CSE does not provide its final approval of the Debt Settlement or requires changes to its terms; the risk that the Company is unable to issue the Settlement Shares on the terms set out herein, within the time contemplated or at all; the risk that the Creditor does not perform its obligations in connection with the Debt Settlement; and adverse changes in the regulatory or political landscape affecting psychedelic research and access, together with the other risk factors described in the Company's continuous disclosure documents available under the Company's profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned that the foregoing list is not exhaustive.
Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Source: Rhelion Life Sciences Corp.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/318914
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of Rhelion Life Sciences' proposed debt settlement?
Rhelion agreed to settle approximately $100,000 owed to an arm's length creditor by issuing 3,333,333 common shares at a deemed price of $0.03 each. The debt relates to a prior Filament obligation. Completion remains subject to final Canadian Securities Exchange approval.
How do Rhelion Life Sciences' newly granted stock options vest?
The 2,300,000 stock options vest in four equal installments at three, six, nine and twelve months following grant. They were granted to employees and consultants of Rhelion and its subsidiaries. Each option can be exercised for one common share at $0.05 for five years from grant.